The lithium dilution method for measurement for cardiac output (LiDCO) is gaining popularity because of its minimally invasive nature and good accuracy. 1 -3 In a previous study, conducted by the authors using isoflurane-anaesthetized ponies, LiDCO measurements differed markedly from those obtained with thermodilution [bias (2 SD) was 2.5 (2.1) litre min 21 , that is 50 (60)% of the values measured by the reference method]. 4 These animals received infusions of xylazine (an a 2 agonist used in veterinary medicine), midazolam, and ketamine during measurements. Because continuous thermodilution cardiac output measurements compared better with bolus thermodilution in that study and experimental error could not be identified, the authors thought that the bias was caused by an interaction between the LiDCO sensor and some of the drugs used. The manufacturer reported that the LiDCO sensor interacts with certain neuromuscular blocking agents, but peerreviewed publications on this topic are not available. Therefore, the authors set up an in vitro experiment in order to identify possible interactions of the LiDCO sensor with certain drugs used in perioperative medicine. It was hypothesized that there were no such interactions. Preliminary results presented in this article have been published in an abstract form.
Methods

Concept
A key for the accuracy of LiDCO is that the sensor should accurately measure lithium concentration in blood. The LiDCO sensor is an ion-selective electrode, comprising a lithiumspecific crown ether ionophore embedded in a polyvinyl chloride membrane. 6 When lithium ions contact the membrane, an increase in trans-membrane electrical potential occurs. This voltage change correlates with changes in lithium concentration. Therefore, the null hypothesis (no drug interaction) can be accepted if the coupling of sensor voltage change and lithium concentration change is maintained regardless of the presence of a test drug. It was arbitrarily decided that the study hypothesis should be rejected if drug-related inaccuracies in lithium detection would lead to .10% bias in cardiac output measurements, as calculated using a published formula. 6 
Experimental protocol
Test drugs and LiCl (LiDCO, London, UK) were dissolved in 0.9% NaCl (Fresenius Kabi, Bad Homburg, Germany) to produce the following solutions: saline (S), saline-lithium (SL), saline-drug (SD), and saline-drug -lithium (SDL). A range of drug concentrations were tested, which are overlapping the ranges of clinical interest as determined from the published literature. Some of the drug concentrations largely exceeded clinical concentrations in order to facilitate comparison with other drugs. The lithium concentration was always 1 mmol litre 21 because this concentration is commonly used during industrial testing of the sensor (E. Mills and D. Band, personal communication) and in research studies. 6 The test solutions (500 or 250 ml) were prepared in glass flasks and placed in a 388C water bath. The average ambient temperature was 24.5 -27.48C. One end of a 30 cm long (0.6 ml priming volume) extension tube was placed in each test solution and the other end was connected to a stopcock (0.2 ml priming volume). The stopcocks were connected to each other and also to a LiDCO sensor (sensor constant: 10.5). The sensor was connected to a cardiac output monitor (LiDCOplus Hemodynamic Monitor, LiDCO) and to the original flow pump supplied with the system. This system allowed selective sampling of each test solution (Fig. 1 ). Sufficient time (at least 1 min) was allowed for the stabilization of voltages before reading. Voltage readings were obtained by touching the 'Sensor interface working normally' virtual button on the touchscreen of the LiDCO monitor and the displayed voltages were manually recorded at 1 decimal point resolution. The accuracy of voltage readings was confirmed before the study using a standalone digital voltage meter. Each experiment (testing a single concentration of a drug) was divided into a control (without drug) and a treatment (with drug) measurement cycle. The control comprised repetitive sampling of S and SL solutions five times and the treatment comprised repetitive sampling of S, SD, and SDL solution five times. A single sensor was used for each major drug treatment (those with multiple concentrations) in an increasing order of concentrations. The sensors were used on the same day they were unpacked (with a single exception when a sensor was used again 2 days later for measurements with butorphanol, atipamezole, acepromazine, and diazepam). The pH values of the test solutions were measured with a pocket pH meter (Amarell, Kreuzwertheim, Germany).
Test drugs
Drugs: acepromazine (Ceva Sante Animale, Libourne, France), atipamezole (Orion Corporation, Espoo, Finland), butorphanol (Richter Pharma, Wels, Austria), clonidine (Boehringer Ingelheim, Barcelona, Spain), detomidine (CP-Pharma, Burgdorf, Germany), dexmedetomidine (Orion, Espoo, Finland), diazepam (Nycomed, Linz, Austria), guaiphenesin (CP-Pharma), ketamine (Vetoquinol, Lure-Cedex, France), lidocaine (Gebro, Fieberbrunn, Austria), medetomidine (Orion), midazolam (Gespag, Linz, Austria), romifidine (Labiana, Terrassa, Spain), S-ketamine (Pfizer, Vienna, Austria), and xylazine (Eurovet Animal Health, Bladel, The Netherlands). Rocuronium (N.V. Organon, Eragny-sur-Epte, France) was used as positive control. Of the drugs tested, xylazine, detomidine, medetomidine, romifidine, and atipamezole are only used in veterinary medicine.
Statistical analysis
The following variables were calculated from the recorded voltages: † Lithium-induced voltage change for controls: voltage of SL2S solutions. † Baseline lithium-induced voltage change: the median value of a pooled data set containing control lithiuminduced voltage changes (SL2S) of all freshly unpacked sensors (not yet exposed to drugs). This was considered to be the most representative value and serves as a common reference point. The base of the LiDCO bias calculation was that lithium concentrations correlate to voltage changes and LiDCO measurements inversely correlate to the areas under lithium dilution curves. 6 It must be emphasized that these values are only mathematically equivalent biases in LiDCO based on in vitro measurements in saline medium. Possible LiDCO biases in vivo depend on the concentration of the active fraction of a drug in the plasma. Descriptive statistics were calculated from the above variables. The normality of data was examined with the Kolmogorov -Smirnov test. Correlations between variables were examined with least square regression analysis. Significance was reported if P,0.05 (SPSS Statistics 17.0, SPSS Inc., IL, USA).
Results
Controls
Control data sets were not normally distributed; therefore, non-parametric statistics were used. Within the group of new sensors (not yet exposed to drugs), the median (range) voltage of saline solutions was 2113.8 (2115.9 to 2103.6) mV, the median lithium-induced voltage change was +10.7 (+10.4 to +11.4) mV, and there was a positive correlation between these variables (r 2 ¼0.47; P,0.001).
The baseline lithium-induced voltage change (+10.7 mV) was similar to that reported previously. 6 
Treatments
During the experiment, concentration-dependent voltage changes were noted when saline was changed to some of the drug solutions (drug-induced voltage change). The highest value (+16.9 mV) was measured with xylazine 500 ng ml 21 solution (Table 1 ). The lithium-induced voltage changes decreased in the presence of certain drugs in a concentration-dependent, linear pattern, and the lowest value (+5.9 mV) was measured with lidocaine 10 000 ng ml 21 solution (Table 1 ). The calculated bias in LiDCO was
.10% for the following drugs at some concentrations: ketamine, xylazine, dexmedetomidine, medetomidine, detomidine, romifidine, clonidine, lidocaine, and rocuronium (Table 1) . It was noted that the drug-induced voltage changes correlated with lithium-induced voltage changes and with calculated biases in LiDCO (Fig. 2) . In order to compare the electrochemical potencies of drugs, the lithium-induced voltage changes were plotted across molar drug concentrations (Fig. 3) . It appeared that a 2 agonists were the most potent and it was followed by rocuronium, ketamine, and lidocaine. The effects of ketamine and xylazine on the LiDCO sensor were additive. Chirality had no effect. Lithium-induced voltage changes stabilized within 10 s during control measurements, but it was slightly longer (≈15 s) in the presence of certain drugs. However, stabilization of sensor voltage was even longer (sometimes 5-7 min) for the drug-induced voltage changes, especially when xylazine was a part of the treatment.
The pH values of the saline solutions were 6.6. Most drugs did not cause any consistent change in pH even at the highest concentrations tested. However, the pH values of rocuronium solutions were 6.0, 5.7, and 5.5 for 1000, 2000, and 4000 ng ml 21 concentrations, respectively. Adding LiCl to these solutions did not change the pH.
Discussion
This in vitro study showed that certain drugs interact with the LiDCO sensor. The interactions are characterized by increased sensor voltage and decreased apparent response to lithium. These effects were concentration-dependent, additive, and were not influenced by chirality. If such interaction occurred in vivo, that would lead to positive biases in LiDCO measurements. A common property of the drug molecules which reacted with the sensor was the presence of an amine group which may become positively charged depending on the pH. a 2 Agonists and rocuronium which were more electrochemically potent in interacting with the sensor possess a cyclic amine group, whereas ketamine and lidocaine do not. The influence of degree of ionization and lipid solubility on the order of observed potency was considered, but based on the authors' estimations (e.g. rocuronium is less lipidsoluble but more electrochemically potent than ketamine), the effect of these factors alone does not explain the results. It is also interesting that lithium (1 mmol litre 21 )
was less electrochemically potent in causing voltage changes than any of the drugs tested (highest concentration: 0.037 mmol litre 21 ). This is counter-intuitive, because the sensor's membrane is the most selective for lithium and the drugs have much larger size than lithium ions. Therefore, it seems unlikely that the drugs would independently compete with lithium ions in passing through the membrane but rather the drugs might change the conductance of the membrane to certain cations (e.g. lithium, sodium, etc.). It was also found that drug-induced voltage changes correlated with calculated biases in cardiac output. This correlation may offer a tool to indicate sensor -drug interactions in vivo (e.g. if voltage change .3 mV). However, further research is needed to develop a method for reliable detection of drug-induced voltage changes in vivo and confirm their relation to LiDCO biases. The calculated LiDCO biases need to be interpreted with caution, because for methodological reasons, supra-clinical drug concentrations were also used in this study. It is possible, however, that xylazine, lidocaine, rocuronium, ketamine, and S-ketamine may reach plasma concentrations sufficient to cause bias in LiDCO in vivo (Table 2) . For example, peak xylazine 7 8 plasma levels near 1000 ng ml 21 and ketamine 9 plasma levels near 3000 ng ml 21 were measured after i.v. bolus injections in animals. Lidocaine plasma levels as high as 7000 ng ml 21 were documented in ponies during lidocaine infusion 10 and 3120 ng ml 21 were measured in a human patient after performing a local anaesthetic technique. 11 Plasma rocuronium levels were close to 1000 ng ml 21 in humans, 12 and rocuronium is known to cause bias in vivo.
Clonidine, detomidine, dexmedetomidine, medetomidine, and romifidine also interacted with the lithium sensor in vitro, but the reported blood levels for these drugs were much lower (,10 ng ml 21 ) than those used in the present study. Therefore, these are unlikely contributors to LiDCO bias in vivo (Table 2 ). Minimal or no interaction can be expected with the following drugs: atipamezole, acepromazine, butorphanol, diazepam, midazolam, and guaifenesin. A weak point of the study is that presumably only free (not protein-bound) and ionized (positively charged) drug molecules would interact with the LiDCO sensor and the concentrations of these reactive drug fractions are difficult or impossible to estimate. However, the fact that these concentrations are less than the total drug concentrations determined in most pharmacokinetic studies should be considered when interpreting the discussion above. The pHs of the test solutions with and without LiCl were similar for most drugs ( 6.6). Therefore, differences in pH should not have an impact on the main conclusions of the study. However, this also means that the ionized fractions of drugs should be different in this study compared with the physiological situation in blood. A further complicating factor is that accumulating drug metabolites may also interact with the sensor in vivo. The main goal of this study was to prove the existence of drug interactions and to identify certain drugs with higher potential to cause biases in LiDCO. These drugs should become targets of future in vivo experiments aimed to prove or disprove these suspicions.
In conclusion, the LiDCO sensor interacted with a number of drugs in vitro but, based on published pharmacokinetic data, only xylazine, ketamine, lidocaine, and rocuronium may reach sufficiently high plasma levels to be associated with clinically relevant biases in LiDCO measurements. These findings need to be confirmed in vivo. Relevant Table 2 Classification of drugs based on the results of this study. Category A: interact with the sensor and may cause bias in LiDCO in vivo. Category B: interact with the sensor but unlikely to cause bias in LiDCO in vivo. Category C: minimal or no interaction was found. *Used exclusively in veterinary medicine changes in sensor voltages due to the presence of drugs may indicate possible interactions with the LiDCO sensor.
